OMass Therapeutics Secures €275M Series C Backing from Bain Capital, Forbion and Novo Holdings

The funding round was co-led by three new investors: Bain Capital Life Sciences, Forbion and Novo Holdings.

Other investors in the round included Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences.

All of OMass Therapeutics’ existing investors also took part in the round. These included Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford.

“This financing comes at an exciting point in OMass’ evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow,” says Ros Deegan, Chief Executive Officer of OMass Therapeutics. “We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic.

“With the backing of an outstanding group of new and existing investors, we are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients.”

“OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs,” adds Evan Greif, Principal at Bain Capital Life Sciences.

“The Company is executing against that vision by advancing OMS1620 and applying its proprietary discovery approach to build a broader pipeline across endocrinology and immunology. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team to support the Company’s strategic and patient-first approach.”

“We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic,” says Max Klement, Partner, Venture Investments at Novo Holdings. “Each of these candidates has the potential to address substantial unmet patient needs in their respective areas of endocrinology and immunology, and we look forward to the Company’s continuing progress.”

Founded in 2016, OMass Therapeutics was spun out of Professor Dame Carol Robinson’s research lab at the University of Oxford. The company was established to turn research in native mass spectrometry into new small-molecule drugs that can target diseases that have been difficult to treat.

OMass Therapeutics uses its proprietary OdyssION drug discovery platform to study and identify potential drug targets. The platform combines advanced mass spectrometry, new biochemical techniques and specialised chemistry.

This technology allows the company to study drug targets in their natural biological environment while maintaining the precision of laboratory-based testing. This approach helps OMass discover potential treatments for targets that have been challenging for traditional drug discovery methods.

Read Also- Microbiotica Raises €42 Mn in Series C Funding to Advance Ulcerative Colitis Treatment